Lorena Garcia Hevia | Drug Delivery Systems | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Lorena Garcia Hevia | Drug Delivery Systems | Best Researcher Award

Universidade de Vigo | Spain

Dr. Lorena García Hevia is a distinguished researcher recognized for her pioneering work at the intersection of nanomedicine, microbiology, and biotechnology. As a member of the Hybrid Nanomaterials Research Group at the Galicia Sur Health Research Institute (IIS Galicia Sur), she has dedicated her career to advancing innovative nanotechnological solutions that address critical biomedical challenges. Her research focuses primarily on the design and application of nanoscale systems to improve therapeutic delivery, particularly within the context of infectious disease management and antimicrobial resistance.Affiliated with the CINBIO (Biomedical Research Center) and the Universidade de Vigo in Spain, Dr. García Hevia brings an interdisciplinary approach that bridges biochemical, genetic, and immunological insights with advanced materials science. Her scientific vision emphasizes the development of intelligent nanocarriers that enhance drug stability, optimize bioavailability, and enable targeted therapy. Through this approach, she contributes to transforming conventional treatments into highly efficient, patient-specific solutions.In her recent publication Nanomedicine for Phage Therapy: Encapsulation Strategies for Enhanced Antimicrobial Efficacy, Dr. García Hevia and her colleagues explore the integration of nanotechnology with bacteriophage therapy to overcome limitations in traditional antimicrobial strategies. Her work demonstrates how encapsulation methods—such as polymeric nanoparticles, liposomes, hydrogels, and nanofibers—can significantly improve the stability, delivery, and therapeutic impact of bacteriophages. These innovative formulations facilitate localized and sustained release, providing powerful alternatives against multidrug-resistant infections.Dr. García Hevia’s research is marked by creativity, precision, and translational relevance. Her investigations into responsive nanocarriers and inorganic nanoparticles have opened new avenues for targeted phage delivery, aligning with global efforts to combat antibiotic resistance through sustainable and effective biotechnological interventions. Beyond her scientific achievements, she is deeply engaged in academic mentorship and collaborative research initiatives that strengthen the connection between laboratory innovation and clinical application.Her contributions continue to shape the evolving field of nanomedicine, positioning her as a leading figure in the development of next-generation antimicrobial therapies. Through her commitment to excellence and scientific innovation, Dr. Lorena García Hevia exemplifies the transformative potential of nanotechnology in redefining the future of infection control and precision therapeutics.

Profile: Google Scholar

Featured Publications

García‐Hevia, L., Bañobre‐López, M., & Gallo, J. (2019). Recent progress on manganese‐based nanostructures as responsive MRI contrast agents. Chemistry–A European Journal, 25(2), 431–441.

García-Hevia, L., Valiente, R., Martín-Rodríguez, R., Renero-Lecuna, C., et al. (2016). Nano-ZnO leads to tubulin macrotube assembly and actin bundling, triggering cytoskeletal catastrophe and cell necrosis. Nanoscale, 8(21), 10963–10973.

Rodrigues, R. O., Baldi, G., Doumett, S., García-Hevia, L., Gallo, J., et al. (2018). Multifunctional graphene-based magnetic nanocarriers for combined hyperthermia and dual stimuli-responsive drug delivery. Materials Science and Engineering: C, 93, 206–217.

García‐Hevia, L., Villegas, J. C., Fernández, F., Casafont, Í., González, J., et al. (2016). Multiwalled carbon nanotubes inhibit tumor progression in a mouse model. Advanced Healthcare Materials, 5(9), 1080–1087.

García-Hevia, L., Casafont, I., Oliveira, J., Terán, N., Fanarraga, M. L., & Gallo, J. (2022). Magnetic lipid nanovehicles synergize the controlled thermal release of chemotherapeutics with magnetic ablation while enabling non-invasive monitoring by MRI for melanoma. Bioactive Materials, 8, 153–164.

Ahmad Saeed | Drug Delivery Systems | Best Researcher Award

Published on by Top Pharmaceutical

Mr. Ahmad Saeed | Drug Delivery Systems | Best Researcher Award

University of Education Lahore | Pakistan

Mr. Ahmad Saeed is a dedicated researcher in the field of analytical chemistry with a strong academic and research background. Currently pursuing a Bachelor of Science in Chemistry at the University of Education, Township Campus, Lahore, he has consistently demonstrated academic excellence with a notable CGPA of 3.60. Throughout his academic journey, he has actively participated in multiple research projects, including the development of biodegradable films containing biological macromolecules impregnated with curcumin for food preservation, investigation of the toxic effects of heavy metals in cosmetics on human health, and the advancement of revolutionized electrochemical sensors utilizing 2D materials as sensor electrodes. He has also contributed to innovative environmental projects, such as Clay Eco Filters, aimed at developing metal nanoparticle-impregnated clay tablets for water purification, and Ecofoil, focused on synthesizing biodegradable films for sustainable food packaging solutions.Mr. Ahmad Saeed has enriched his academic experience through hands-on laboratory work as a Graduate Research Assistant, where he worked extensively on projects involving the synthesis of nanomaterials for environmental and analytical applications. As a Teaching Assistant, he contributed to the academic development of students by assisting in atomic spectrophotometry courses, grading assignments, and providing academic guidance. He has participated in major conferences, including the International Conference on Trends and Research in Chemistry and the International Conference on Material Chemistry and Industrial Technologies, serving as both an organizer and a participant, thus gaining exposure to scholarly dialogues and academic networking.His research contributions are reflected in several scholarly publications, including Multivariate Statistical Analysis of Cosmetics Due to Potentially Toxic/Heavy Metal(loid) Contamination: Source Identification for Sustainability and Human Health Risk Assessment published in Sustainability, Structural Development of Curcumin: A Natural Product Arsenal for Diverse Therapeutic Targets – Seizing Opportunities Through Serendipity and Rational Design in the Journal of Molecular Structure, and FDA-Approved Sulfonamides-Containing Molecules: An Insightful Review on the Synthesis Strategy, Medical Indication, and Their Binding Mode under review in Chemistry and Biodiversity. These works highlight his interest in environmental sustainability, analytical chemistry, natural products, and biomedical applications.

Profile: Orcid

Featured Publications

Ahmed, M., Basheer, S., Mughram, M. H. A., Iqbal, D. N., Qamar, S., Saeed, A., Batool, R., Sanaullah, M., Raza, H., & Hussain, R. (2025). Structural development of curcumin: A natural product arsenal for diverse therapeutic targets—Seizing opportunities through serendipity and rational design. Journal of Molecular Structure.

Aslam, A. A., Ahmed, M., Mughram, M. H. A. L., Habib-ur-Rahman Mahmood, M., Basheer, S., Hussain, R., Eiman, E., Sanaullah, M., Raza, H., Saeed, A., et al. (2025). Sulfonamides as a promising scaffold in drug discovery: An insightful review on FDA-approved molecules, synthesis strategy, medical indication, and their binding mode. Chemistry and Biodiversity.

Ahmed, M., Basheer, S., Mughram, M. H. A., Iqbal, D. N., Qamar, S., Saeed, A., Batool, R., Sanaullah, M., Raza, H., & Hussain, R. (2025). Multivariate statistical analysis of cosmetics due to potentially toxic/heavy metal(loid) contamination: Source identification for sustainability and human health risk assessment. Sustainability.

Yilong Wang | Drug Delivery Systems | Best Researcher Award

Published on by Top Pharmaceutical

Yilong Wang | Drug Delivery Systems | Best Researcher Award

Prof Yilong Wang, Beijing Tiantan Hospital, Capital Medical University, China

Dr. Yilong Wang, Executive Vice President of Beijing Tiantan Hospital, Capital Medical University, is a distinguished neurologist and scientist. With an MD and PhD in Neurology, he has pioneered research in stroke and rare neurological disorders. Author of 301 impactful journal articles and holder of 12 patents, his innovative work spans drug delivery systems and precision medicine. Honored with the 2023 Paul Dudley White International Award, he has also authored several clinical neurology manuals. His cutting-edge contributions, including transcranial drug delivery devices, underscore his commitment to advancing global healthcare. 🌍📚

Publication Profile

google scholar

Academic and Professional Background

Professor Yilong Wang 🎓, an accomplished neurologist, earned his MBBS and MSc from North China University of Science and Technology, followed by an MD and PhD in Neurology from Capital Medical University. He completed postdoctoral training at the University of San Francisco 🌉. Currently serving as Executive Vice President and Chief Scientist at Beijing Tiantan Hospital 🏥, Prof. Wang has led groundbreaking research in stroke and rare neurological diseases 🧠. Over the past five years, he has published 72 high-impact papers 📄, holds 12 patents, and made significant strides in precision medicine and drug delivery systems 💊, earning prestigious accolades like the 2023 Paul Dudley White International Award 🏆.

Editorial Appointments

 Professor Yilong Wang 🧑‍⚕️ holds prominent editorial roles, serving as the Assistant Editor-in-Chief of Stroke & Vascular Neurology 📚, Deputy Editor-in-Chief of the Chinese Journal of Cerebrovascular Diseases 🧠, and as an editorial board member of the Chinese Journal of Stroke ✍️. His collaborative efforts extend to leading institutions, including the Frontier Medical Interdisciplinary and Translational Center at the National Center for Neurological Disorders 🌐 and the Beijing Brain Science and Brain-Inspired Research Center 🧬. These partnerships underscore his commitment to advancing neurological research and fostering innovation in cerebrovascular and brain science 🏥.

Professional Memberships

Professor Yilong Wang 🧑‍⚕️ plays key leadership roles in various prestigious organizations. He serves as Vice Chairman of the Expert Committee for the National Health Commission’s Million Disability Reduction Project 🌟, demonstrating his dedication to public health. Prof. Wang is also the Deputy Leader of the Youth Group of the 8th Committee of the Neurology Branch of the Chinese Medical Association 🧠. Additionally, he is the Executive Vice Chairman of the Youth Working Committee of the Chinese Stroke Association 💼 and Vice Chairman of the Cerebral Small Vessel Disease Branch of the Chinese Stroke Association 🩺, driving innovation in neurological care.

Areas of Research

Professor Yilong Wang 🧑‍⚕️ specializes in clinical and translational research on cerebrovascular diseases and rare neurological disorders 🧠, with a focus on interdisciplinary medical-engineering innovations ⚙️. His research includes precision medicine for ischemic stroke 🩺, developing technologies for accurate diagnosis and treatment. He pioneers innovative drug delivery systems 💊, utilizing skull bone marrow-dura-lymphatic pathways to bypass the blood-brain barrier for safe intracranial drug delivery. Prof. Wang also investigates the pathogenesis, diagnostics, and interventions for cerebral small vessel disease and rare neurological disorders 🌐. Additionally, he advances intelligent skull flaps, smart drug delivery systems, and brain-computer interfaces 🤖.

Contributions

Professor Yilong Wang 🧑‍⚕️, a renowned neurologist at Beijing Tiantan Hospital 🏥, has revolutionized stroke and rare neurological disease research 🧠. Over the past five years, he has published 72 high-impact papers in top journals like NEJM, JAMA, and BMJ 📄 and holds 12 patents, with 2 successfully translated into clinical applications 🌟. His innovations include extending the time window for dual antiplatelet therapy, developing drugs for microcirculation disorders, and pioneering skull-based drug delivery systems to bypass the blood-brain barrier 💊. Recipient of the 2023 Paul Dudley White International Award 🏆, Prof. Wang has advanced precision medicine and rare disease research, improving global patient care 🌍.

Research Focus

Professor Yilong Wang is a distinguished researcher focusing on neurology, particularly stroke epidemiology, prevention, and management, and the application of artificial intelligence (AI) in healthcare. His work spans from analyzing stroke prevalence in China to exploring treatment strategies, including antiplatelet therapies and real-world applications of AI in medical practice. With a robust emphasis on stroke prevention, outcomes, and treatment innovation, his contributions bridge advanced research and clinical practice. Wang’s research also addresses the broader implications of healthcare technologies, underscoring their transformative potential. 🧠💊📊

Publication Top Notes

Artificial intelligence in healthcare: past, present and future

Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults

Clopidogrel with aspirin in acute minor stroke or transient ischemic attack

Stroke in China: advances and challenges in epidemiology, prevention, and management

Near-real-time monitoring of global CO2 emissions reveals the effects of the COVID-19 pandemic

Rivaroxaban for stroke prevention after embolic stroke of undetermined source

Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study

Summer soil drying exacerbated by earlier spring greening of northern vegetation